Trial Profile
A Phase I/II Study of Algenpantucel-L (HyperAcute Pancreas) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jun 2015
Price :
$35
*
At a glance
- Drugs Algenpantucel-L (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2007 New trial record.